Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gulf Pharmaceutical Industries PSC's Revenue for the
three
months ended in Jun. 2026 was د.إ300 Mil. Gulf Pharmaceutical Industries PSC's average Accounts Receivable for the
three
months ended in Jun. 2026 was د.إ608 Mil.
Hence, Gulf Pharmaceutical Industries PSC's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.49.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gulf Pharmaceutical Industries PSC Receivables Turnover Related Terms
Gulf Pharmaceutical Industries PSC Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADX:JULPHAR vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a Receivables Turnover of 0.49 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #107 out of 119 companies in the Medical Distribution industry, placing it in the top 89.9%.
Is Gulf Pharmaceutical Industries PSC's Receivables Turnover too high?
Gulf Pharmaceutical Industries PSC's current Receivables Turnover is 0.49. The Medical Distribution industry median Receivables Turnover is 4.90. Gulf Pharmaceutical Industries PSC's value of 0.49 is 90% below this industry median. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #107 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #107 out of 119 companies for Receivables Turnover. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. The industry median Receivables Turnover is 4.90. Gulf Pharmaceutical Industries PSC's value of 0.49 is 90% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.90, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gulf Pharmaceutical Industries PSC's current Receivables Turnover of 0.49 is 90% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current Receivables Turnover is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.11, compared to a current price of د.إ1.02 — trading 8.1% below its estimated fair value. The current Receivables Turnover is 0.49 and 90% below the Medical Distribution industry median of 4.90. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current Receivables Turnover is 0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.02 is trading 8.1% below its estimated GF Value™ of د.إ1.11.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
Receivables Turnover: 0.49
GF Value™: د.إ1.11 vs. price of د.إ1.02 (8.1% below fair value)
Industry Position: 90% below the Medical Distribution median (#107 of 119)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
64GF Score
Get the complete analysis for ADX:JULPHAR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
